AYTU BioPharma
AYTU
22 hedge funds and large institutions have $4.66M invested in AYTU BioPharma in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 2 closing their positions.
71% more capital invested
Capital invested by funds: $2.73M → $4.66M (+$1.93M)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
5% more funds holding
Funds holding: 21 → 22 (+1)
0.55% more ownership
Funds ownership: 45.09% → 45.64% (+0.55%)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$25.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.12K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$6.83K |
| 5 |
Renaissance Technologies
New York
|
+$5.95K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Prudential Financial
Newark,
New Jersey
|
-$31.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.48K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$283 |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$212 |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4 |
AYTU Hedge Fund Activity: Q3 2023 in Review
22 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2023, worth a combined $4.66M — up 71% from $2.73M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new AYTU positions and 2 closed out — a net gain of 1 holder — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Northern Trust, opening a new position worth an estimated $25.5K. The largest seller was Prudential Financial, exiting entirely with an estimated $31.3K sold.
- 22 institutional investors held AYTU BioPharma (AYTU) as of Q3 2023, up from 21 in Q2 2023.
- Funds reported $4.66M of AYTU BioPharma stock for Q3 2023, up 71% quarter-over-quarter.
- 3 funds opened new AYTU BioPharma positions in Q3 2023 and 2 closed out, a net change of +1 holder.
- The largest AYTU BioPharma buyer in Q3 2023 was Northern Trust, an estimated $25.5K added.
- The largest AYTU BioPharma seller in Q3 2023 was Prudential Financial, an estimated $31.3K sold.
Based on aggregated 13F filings for Q3 2023.